Stela Dragomanova
New Myrtenal–Adamantane Conjugates Alleviate Alzheimer’s-Type Dementia in Rat Model
Dragomanova, Stela; Lazarova, Maria; Munkuev, Aldar; Suslov, Evgeniy; Volcho, Konstantin; Salakhutdinov, Nariman; Bibi, Amina; Reynisson, Jóhannes; Tzvetanova, Elina; Alexandrova, Albena; Georgieva, Almira; Uzunova, Diamara; Stefanova, Miroslava; Kalfin, Reni; Tancheva, Lyubka
Authors
Maria Lazarova
Aldar Munkuev
Evgeniy Suslov
Konstantin Volcho
Nariman Salakhutdinov
Amina Bibi
Johannes Reynisson j.reynisson@keele.ac.uk
Elina Tzvetanova
Albena Alexandrova
Almira Georgieva
Diamara Uzunova
Miroslava Stefanova
Reni Kalfin
Lyubka Tancheva
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disease associated with memory impairment and other central nervous system (CNS) symptoms. Two myrtenal–adamantane conjugates (MACs) showed excellent CNS potential against Alzheimer’s models. Adamantane is a common pharmacophore for drug design, and myrtenal (M) demonstrated neuroprotective effects in our previous studies. The aim of this study is to evaluate the MACs’ neuroprotective properties in dementia. Methods: Scopolamine (Scop) was applied intraperitoneally in Wistar rats for 11 days, simultaneously with MACs or M as a referent, respectively. Brain acetylcholine esterase (AChE) activity, noradrenaline and serotonin levels, and oxidative brain status determination followed behavioral tests on memory abilities. Molecular descriptors and docking analyses for AChE activity center affinity were performed. Results: M derivatives have favorable physicochemical parameters to enter the CNS. Both MACs restored memory damaged by Scop, showing significant AChE-inhibitory activity in the cortex, in contrast to M, supported by the modeling analysis. Moderate antioxidant properties were manifested by glutathione elevation and catalase activity modulation. MACs also altered noradrenaline and serotonin content in the hippocampus. Conclusion: For the first time, neuroprotective properties of two MACs in a rat dementia model were observed. They were stronger than the natural M effects, which makes the substances promising candidates for AD treatment.
Citation
Dragomanova, S., Lazarova, M., Munkuev, A., Suslov, E., Volcho, K., Salakhutdinov, N., …Tancheva, L. (2022). New Myrtenal–Adamantane Conjugates Alleviate Alzheimer’s-Type Dementia in Rat Model. Molecules, 27(17), Article 5456. https://doi.org/10.3390/molecules27175456
Journal Article Type | Article |
---|---|
Acceptance Date | Aug 22, 2022 |
Online Publication Date | Aug 25, 2022 |
Publication Date | Aug 25, 2022 |
Publicly Available Date | May 30, 2023 |
Journal | Molecules |
Publisher | MDPI |
Volume | 27 |
Issue | 17 |
Article Number | 5456 |
DOI | https://doi.org/10.3390/molecules27175456 |
Public URL | https://keele-repository.worktribe.com/output/424401 |
Publisher URL | https://www.mdpi.com/1420-3049/27/17/5456 |
Files
New Myrtenal-Adamantane Conjugates Alleviate Alzheimers-Type Dementia in Rat Model.pdf
(3.5 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Accessing active fragments for drug discovery utilising nitroreductase biocatalysis.
(2024)
Journal Article
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search